Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi Earnings Emphasize Need For Medivation Buy

Executive Summary

Sanofi clearly would benefit from its proposed $9.3bn purchase of Medivation Inc. based on the French company's first quarter earnings, which show a pharmaceuticals business that's suffering from competition, US drug pricing pressures and foreign currency exchange issues.

Advertisement

Related Content

Sanofi Could Pursue Other Oncology M&A Targets After Medivation Loss
Medivation Gets Hostile After Sanofi's "Misleading" Maneuvers
Sanofi Seeks Medivation Board Overhaul As Buyout Bid Remains Rejected
Stockwatch: Big Pharma Strikes Back In Earnings War
Sanofi Goes Public With Hostile Medivation Bid
Sanofi Pasteur, Merck Part Ways On European Vaccines Venture
Diabetes Decline Continues On Schedule At Sanofi
Bold Brandicourt Plots Mega Sanofi And Boehringer Animal, Consumer Asset Swap
Brandicourt's 'Big Reveal' Falls Flat For Sanofi
Sanofi-Aventis acquires Genzyme for $74 a share plus contingent $14 per share

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC065090

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel